Abstract | BACKGROUND AND PURPOSE: METHODS AND RESULTS: The 59 Japanese patients with a recent history of stroke were randomly assigned to a group without vitamin treatment (Group 1, n = 29) and to a group with treatment with both folic acid and vitamin B(12) for 2 months (Group 2, n = 30). The CF6 level was elevated in the patients with stroke compared with that in controls (n = 64) at admission. In a multiple regression model, the plasma CF6 level was weakly correlated to the total Hcy (tHcy) level. In Group 1, the plasma tHcy and CF6 levels were unchanged. In Group 2, however, they were both decreased, and there was a weak positive correlation between the decreases in plasma levels of CF6 and tHcy. CONCLUSION: CF6 is elevated in patients with stroke independently of risk factors. Since Hcy and vitamin treatment affect CF6 levels in stroke, CF6 appears to be a novel molecule for the pathogenesis and treatment of stroke.
|
Authors | Tomohiro Osanai, Naoto Fujiwara, Satoko Sasaki, Norifumi Metoki, Genta Saitoh, Hirofumi Tomita, Takashi Nishimura, Shuji Shibutani, Hiroaki Yokoyama, Yoshiyuki Konta, Koji Magota, Ken Okumura |
Journal | Annals of medicine
(Ann Med)
Vol. 42
Issue 1
Pg. 79-86
( 2010)
ISSN: 1365-2060 [Electronic] England |
PMID | 20092401
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Oxidative Phosphorylation Coupling Factors
- Homocysteine
- Vitamin B Complex
- Folic Acid
- F(6) ATPase
- Mitochondrial Proton-Translocating ATPases
- Vitamin B 12
|
Topics |
- Aged
- Female
- Folic Acid
(therapeutic use)
- Homocysteine
(blood)
- Humans
- Japan
- Male
- Middle Aged
- Mitochondrial Proton-Translocating ATPases
(blood)
- Oxidative Phosphorylation Coupling Factors
(blood)
- Stroke
(blood, drug therapy)
- Vitamin B 12
(therapeutic use)
- Vitamin B Complex
(therapeutic use)
|